Love Pharma Inc (TSE:JOLT) has released an update.
Jolt Health Inc. has canceled its arrangement to acquire a transdermal drug delivery technology and is redirecting its efforts to the artificial intelligence sector, aiming to drive innovation in healthcare. The company’s CEO expressed confidence in AI to strengthen their health and wellness offerings and is optimistic about recent interest rate cuts boosting the economy. Jolt Health maintains exclusive licenses for various therapeutic and pharmaceutical products across Europe, the UK, and North America.
For further insights into TSE:JOLT stock, check out TipRanks’ Stock Analysis page.
